The Josep Carreras Leukaemia Research Institute aims to bring the cure of leukaemia and other hematologic malignancies to the patients, translating the research results into new treatments and diagnostic tools. We promote the transfer of research results building alliances at a global level, while contributing to the economic development of the territory and the sustainability of research.
To learn more about our technologies or to submit an invention report, please contact a member of our licensing team, or email innovation@carrerasresearch.org
EPICART
EPICART is a risk stratification tool that employs a methylation signature that accurately predicts the treatment outcome of B-malignancy patients treated with CD19 CAR T-cell therapy.
HDAC7
Two compounds have been developed as a combinatorial therapy for the induction of HDAC7 expression, impairing t(4;11) pro-B-ALL cells’ proliferation and improving the patients’ prognosis.
Leukos Biotech is a spin-off company from IJC, based on the research of Dr. Ruth Muñoz-Risueño, focused on developing new treatments and diagnostic tools for leukemia.
www.leukosbiotech.com
OneChain Immunotherapeutics is a spin-off company from IJC and ICREA, based on the research led by Dr. Pablo Menéndez, with the aim to develop immunotherapies against haematological neoplasms using CAR-T candidates against different antigens.
www.onechaintx.com
-edit-20240304133439.jpg?locale=en)
